Allergy/Imm

sponsor

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Kaliner MA et al. - No significant between-treatment differences were determined for the average 2-week percent changes from baseline for congestion, runny nose, sneezing, itchy nose, and ocular symptoms, although olopatadine had a faster onset of action for reducing all symptoms. Both treatments were safe and well tolerated. Olopatadine and fluticasone nasal sprays both reduced nasal and ocular SAR symptoms with no significant between-treatment differences except for a faster and greater onset of action with olopatadine.

Related Articles

Time Interval and the Factors Associated with the Development of Asthma in Patients with Allergic Rhinitis
Lung, 10/09/09    Relevance Score: 69%

Nonallergic Rhinitis Symptoms More Severe Than Allergic Rhinitis
ScienceDaily, 10/06/09    Relevance Score: 69%

Allergic rhinitis, histamine, and otitis media
Allergy and Asthma Proceedings, 10/09/09    Relevance Score: 68%

Trichuris suis ova therapy for allergic rhinitis: A randomized, double-blind, placebo-controlled clinical trial
Journal of Allergy and Clinical Immunology, 10/07/09    Relevance Score: 68%

Mechanisms and clinical implications of glucocorticosteroids in the treatment of allergic rhinitis
Clinical and Experimental Immunology, 10/05/09    Relevance Score: 68%

Today in Clinical Pharmacology...keeping you current

Infected atopic dermatitis lesions contain pharmacologic amounts of lipoteichoic acid
Journal of Allergy and Clinical Immunology, 12/08/09

Effects of budesonide and formoterol on allergen-induced airway responses, inflammation, and airway remodeling in asthma
Journal of Allergy and Clinical Immunology, 12/08/09

Effects of biological drug adalimumab on tumour necrosis factor-alpha-converting enzyme activation
Immunology & Cell Biology, 12/08/09